Clinical Trial Update: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating recurrence-directed therapy with or without androgen-deprivation therapy in patients with radio-recurrent oligometastatic horm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer | Phase 2 | Status: RECRUITING